Fujita Health University

Perseus Proteomics Inc.

University of Miyazaki

Institute for Antibodies Co., Ltd.

Osaka University

Other

Takara Shuzo Co., Inc.

Amano Enzyme Inc.

Osaka Prefecture University Public Corporation

Medical Biological Laboratories Co., Ltd.

National Institute of Infectious Diseases

Kurosawa, Yoshikazu

Yoshikazu Kurosawa

Gene Kurosawa

Kazuhiro Morishita

Yoshinori Ukai

Yoshitaka Iba

Katsuyuki Mitomo

Yoshinobu Okuno

Yasushi Akahori

Nobuko Ohshima

Fumiko Nomura

Lilin Zhang

Yukio Sudo

Motohide Takahashi

Mariko Sumitomo

Atsushi Sugioka

Masachika Azuma

Ikunoshin Kato

Nobuhiro Takahashi

Kazuhiro Suzuki

Fusao Kimizuka

Kimikazu Hashino

Keiko Ogawa

Katsushi Kouda

Kimiyasu Shiraki

Kiyotoshi Sekiguchi

Sari Fujiyama

Shunji Kozaki

Nobuhiro Hayashi

Toshio Honda

Chiho Muramatsu

Koiti Titani

Kazuki Matsuda

Susumu Tsustumi

Akihiko Takasaki

Miwa Morita

Kazuko Kaneda

Maiko Kurosawa

Masafumi Mukamoto

Tomoko Kohda

Kazuhiko Morino

Midori Shinohara

Kazuhiro Miyazaki Medical College Dept Of Biochemistry Morishita

Yoshinori c/o Inst Antibodies Co Ltd Ukai

Masachika c/o Inst Antibodies Co Ltd Azuma

Susumu Tsutsumi

Nobuhiro c/o The Faculty Of Agriculture Takahashi

Atsushi Viequ Court Denjiyama Sugioka

Noriko Satou

Mototaka Sugiura

Miho Tanaka

It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.

Antibody which specifically reacts with human integrin A6B4

Provided is a method of providing an effective means as a countermeasure for handling a pandemic of an influenza virus. The resistance to a type A influenza virus is determined using, as an indicator, the presence or otherwise of antibodies using the VH1-69 gene in a biological sample originating from a subject.

Method of determining resistance to influenza virus

Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.

Influenza virus-neutralizing antibody and screening method therefor

An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).

Antibody capable of specifically recognizing transferrin receptor

The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.

The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.

Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same

To provide a method for detecting cellular DNA damage by specifically recognizing molecules responsive to DNA strand breaks. A method for detecting DNA damage in cells, which comprises administering in vivo, to cells, an antibody against a cell membrane surface antigen that is expressed in cells undergoing DNA strand breaks to a greater extent than in cells not undergoing DNA strand breaks in an environment that causes DNA damage, and analyzing the expression status of the cell membrane surface antigen.

Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D

Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination of two or more of the antibodies and which has a high neutralizing activity.

Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody

An antibody library is prepared by selecting a light chain variable region capable of binding to the variable region of heavy chain to reproduce an active conformation and using the same. Because of being capable of maintaining the diversity of the heavy chain variable region at a high ratio in vitro, the antibody library of the present invention is expected as enabling the acquisition of antibodies with various binding activities.

Antibody library

It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.

Anti-IgSF4 antibody and utilization of the same

The present invention provides camel antibody libraries that maintain in vivo diversity of camelid antibody variable region genes. The in vivo diversity of antibody variable region genes can be accomplished by, for example, mixing genes derived from a plurality of animals or modifying gene amplification conditions. Conventional methods yield only VHHs with limited repertoire diversity. However, the present invention provides libraries comprising genes encoding functional VHHs with sufficient repertoire size. According to the present invention, libraries that enable to freely obtain VHHs against arbitrary antigens are provided. VHHs have excellent solubility and stability, and show a reactivity that usually cannot be expected from tetrameric IgGs.

Methods of constructing camel antibody libraries

This invention provides an antibody having antigen binding activity and which has a heavy chain constant region into which has been introduced an RGDS amino acid sequence giving the antibody affinity for cells, including macrophages. The antibody exhibits artificial cell adhesive activity which is the newly expressed activity that results from insertion of the RGDS amino acid sequence. This antibody having artificial cell adhesive activity can accelerate the phagocytosis of macrophages, and can activate other effector cells. Therefore, this antibody contributes to the self-defense mechanism.

Artificial antibody

Growing community of inventors

Nagoya, Japan

Yoshikazu Kurosawa